Indiva: Top 10 Undervalued Drug Manufacturers Industry Sector Stocks on TSX Venture Exchange (NDVA)
Indiva is now ranked among the top 10 undervalued stocks in the Drug Manufacturers industry on the TSX Venture Exchange. A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of a company. Valuation methodology provided by Stockcalc (see below).
All data provided as-at market close September 01, 2022. The list is sorted by stocks with the greatest percentage difference between valuation and price. Indiva Indiva Ltd is engaged in supplying medical cannabis. The company offers dried cannabis flowers and oils. It also offers sativas, indicas, and hybrids. The company operates in one segment that is the Production of medical marijuana. Indiva is listed under NDVA on the TSX Venture Exchange.
| Symbol | Name | Close Price | Shares Outstanding | P/E | P/B | Cash per Share | Net Cash per Share |
|---|---|---|---|---|---|---|---|
| CANB-X | CanadaBis Capital | 0 | 0 | 0 | 0 | 0 | 0 |
| NU-X | NeutriSci International | 0 | 0 | 0 | 0 | 0 | 0 |
| FLWR-X | The Flowr | 0 | 0 | 0 | 0 | 0 | 0 |
| RTI-X | Radient Technologies | 0 | 0 | 0 | 0 | 0 | 0 |
| SBBC-X | Simply Better Brands | 0 | 0 | 0 | 0 | 0 | 0 |
| SUGR-X | SugarBud Craft Growers | 0 | 0 | 0 | 0 | 0 | 0 |
| NHP-X | Lumiera Health | 0 | 0 | 0 | 0 | 0 | 0 |
| NDVA-X | Indiva | 0 | 0 | 0 | 0 | 0 | 0 |
| KHRN-X | Khiron Life Sciences | 0 | 0 | 0 | 0 | 0 | 0 |
| ROMJ-X | Rubicon Organics | 0 | 0 | 0 | 0 | 0 | 0 |
More about Indiva
Drug Manufacturers: Major, global pharmaceutical manufacturers offering a broad and diverse line of drug and healthcare products; industry leaders that have made a significant commitment to the research and development of a long pipeline of drugs.. Stocks in this category are held primarily for capital appreciation.
Artificial intelligence at Report on Business
Artificial Intelligence at Report on Business Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.
